NYBA
New York Biotechnology Association
 
 
More...
NYBA: Member News
Archived News | Press Release | NYBA News
 
 
 
Regeneron Pharmaceuticals, Inc.
Headline: Lowey Calls For Job Creation Policies At Growing Westchester Business
Date: 01-Feb-2010
... .
Details »
 
 
OSI Pharmaceuticals Inc.
Headline: FDA Extends Review Period For Tarceva Application For First-Line Maintenance Use In
Advanced Non-Small Cell Lung Cancer
Date: 15-Jan-2010
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva(R) (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an add... .
Details »
 
 
EpiCept Corporation
Headline: EpiCept Announces Reverse Split Of Common Stock
Date: 14-Jan-2010
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) (the "Company") announced today that a previously authorized 1-for-3 reverse stock split of its common stock has been consummated and will be in effect as follows: Nasdaq Capital Market The reverse stock split will be in effect at the start of trading on Friday, January 15, 2010 on a 1-... .
Details »
 
 
EpiCept Corporation
Headline: EpiCept Announces Commercial Licensing Agreement For Ceplene(R) With Meda In Europe
and Pacific Rim
Date: 11-Jan-2010
Agreement Includes Upfront Payment, Milestones and Product Royalties EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it has entered into an exclusive commercialization agreement for Ceplene(R) (histamine dihydrochloride) with Meda AB, (OMX Nordic Exchange: MEDA-A-ST) a leading international specialty pharmaceutical company based in Stockholm. Ceple... .
Details »
 
 
Genentech Inc.
Headline: FDA Approves ACTEMRA® (tocilizumab) For The Treatment Of Moderately To Severely
Active Rheumatoid Arthritis
Date: 08-Jan-2010
-- First-in-class, IL-6 receptor-inhibiting monoclonal antibody approved based on largest clinical development program in rheumatoid arthritis to date  -- South San Francisco, Calif. --  January 8, 2010 --  Genentech, Inc. , a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approv... .
Details »
 
 
Pfizer Inc.
Headline: Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab
(CP-675,206) In Advanced Melanoma
Date: 07-Jan-2010
Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab.... .
Details »
 
 
Pfizer Inc.
Headline: Pfizer And Strides Arcolab To Collaborate On Generic Products
Date: 06-Jan-2010
Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint... .
Details »
 
 
Pfizer Inc.
Headline: European Commission Approves New Intravenous Formulation Of Pfizer’s Revatio®
(Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Date: 04-Jan-2010
Revatio is Only PAH Treatment in Its Class with Approved I.V. Formulation, Allowing Patients to Continue Treatment While Unable to Use Oral Therapy NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission has approved Revatio® (sildenafil) solution for injection for patients who are currently prescribed oral Revatio and who are temporarily... .
Details »
 
 
Pfizer Inc.
Headline: Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine
Date: 30-Dec-2009
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine. As a result, the review will continue beyond the p... .
Details »
 
 
Pfizer Inc.
Headline: Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer
(NSCLC) For Futility
Date: 29-Dec-2009
Findings to be Incorporated into Ongoing Clinical Trial Program NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC... .
Details »
 
   
  © 2008 New York Biotechnology Association HOME | ABOUT NYBA | CONTACT US | SITE MAP Website by Axxiem